All the news Showing 10 of 51 articles from: NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Fatty liver disease raises the risk of cardiovascular disease in people with HIV Keith Alcorn / 28 March 2022 Non-alcoholic fatty liver disease or liver fibrosis raised the risk of cardiovascular disease in people with HIV who have either normal body weight or are under 60, Italian and Canadian ... Metabolic disorders cause liver damage in people with HIV more often than viral hepatitis in lower-income countries Keith Alcorn / 01 March 2022 Liver fibrosis in people with HIV in low- and middle-income countries was more often attributable to metabolic disorders than viral hepatitis, a six-country comparative study has found.The findings, presented last ... Advanced fibrosis in people with NAFLD increases the risk of liver complications Keith Alcorn / 08 December 2021 Advanced liver fibrosis in people with non-alcoholic fatty liver disease was associated with an increased risk of liver-related complications, a prospective study in the United States has found. Fat accumulation in the liver, ... People with HIV taking newer antiretrovirals at higher risk of fatty liver disease Keith Alcorn / 08 October 2021 People with HIV were more likely to develop fatty liver disease if they took antiretroviral treatment that contains an integrase inhibitor or tenofovir alafenamide (TAF), a German research group has found. Non-alcoholic ... Resmetirom reduces liver fat and fibrosis in people with NASH Liz Highleyman / 01 July 2021 Resmetirom, a thyroid hormone receptor agonist, appeared to reduce liver fat and fibrosis, as determined by biomarkers and non-invasive imaging, in people with non-alcoholic steatohepatitis (NASH), according to a presentation at the 2021 International ... Food insecurity raises the risk of death in people with fatty liver disease Keith Alcorn / 28 June 2021 Food insecurity – limited or unreliable food supplies due to poverty – was associated with an increased risk of death in US adults with non-alcoholic fatty liver disease (NAFLD) or advanced fibrosis ... HIV doubles the risk of liver fibrosis by middle-age, without viral hepatitis Michael Carter / 26 January 2021 Having HIV almost doubles the risk of liver fibrosis, according to European research published in the online edition of the Journal of Infectious Diseases. Investigators in Denmark and the Netherlands ... Semaglutide alone or in combination regimens shows promise for NASH Liz Highleyman / 18 December 2020 Semaglutide, a medication approved to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis, researchers reported at the AASLD virtual Liver Meeting. What's more, ... Lanifibranor improves NASH in 24-week trial Keith Alcorn / 18 December 2020 Twenty-four weeks of treatment with lanifibranor, a drug designed to treat NASH, improved liver fibrosis in 42% of people treated in a phase 2b clinical trial, Professor Sven Francque of Antwerp ... Efruxifermin improves liver fat and fibrosis in people with NASH Keith Alcorn / 15 December 2020 Efruxifermin reduced liver fat and improved liver inflammation and fibrosis in the majority of people with NASH who received it in a phase 2a trial but nausea and vomiting led 10% of ... ← First12345...6Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive